arrow
P

Paul C. Brown

us food & drug administration (fda)
H指数:17
被引数:990

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform

在肝芯片平台上测量药物诱导性肝损伤常用生物标志物所面临的挑战与解决方案

2025-10-010
PRE
SC delivery of ultra-high concentration (up to 500 mg/mL) protein microparticle suspensions: pharmacokinetics, efficacy, biodistribution, and immunogenicity

皮下注射递送超高浓度(高达500 mg/mL)蛋白质微球悬液:药代动力学、疗效、生物分布和免疫原性

2025-05-020
PRE
Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug Development
2023-10-0911
PRE
IVIVE: Facilitating the Use of In Vitro Toxicity Data in Risk Assessment and Decision Making
TOXICS
IF4.1
2022-05-0165
OAAI
3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration
2021-06-16120
OAAI
An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)

FDA/CDER对非临床测试策略的看法: 经典毒理学方法和新方法方法学 (NAMs)

2020-07-01103
PREAI
Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation
2020-06-0127
OAAI
Summary Report of PQRI Workshop on Nanomaterial in Drug Products: Current Experience and Management of Potential Risks
2014-11-2518
OAAI
Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials
2014-10-0122
OAAI